BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
USA - NASDAQ:BIOX - KYG1117K1141 - Common Stock
1.92 USD
-0.08 (-4%)
1.95 USD
+0.03 (+1.56%)
Taking everything into account, BIOX scores 3 out of 10 in our fundamental rating. BIOX was compared to 82 industry peers in the Chemicals industry. Both the profitability and financial health of BIOX have multiple concerns. BIOX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BIOX had negative earnings in the past year.
BIOX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
BIOX's Return On Assets of -1.13% is on the low side compared to the rest of the industry. BIOX is outperformed by 64.63% of its industry peers.
BIOX has a Return On Equity of -2.94%. This is in the lower half of the industry: BIOX underperforms 62.20% of its industry peers.
BIOX has a Return On Invested Capital of 3.08%. This is comparable to the rest of the industry: BIOX outperforms 41.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROIC | 3.08% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of BIOX (5.69%) is worse than 62.20% of its industry peers.
With an excellent Gross Margin value of 39.83%, BIOX belongs to the best of the industry, outperforming 84.15% of the companies in the same industry.
BIOX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIOX is destroying value.
BIOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BIOX has a debt to FCF ratio of 9.52. This is a negative value and a sign of low solvency as BIOX would need 9.52 years to pay back of all of its debts.
BIOX's Debt to FCF ratio of 9.52 is fine compared to the rest of the industry. BIOX outperforms 64.63% of its industry peers.
BIOX has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
BIOX's Debt to Equity ratio of 0.28 is amongst the best of the industry. BIOX outperforms 80.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Altman-Z | N/A |
ROIC/WACC0.35
WACC8.9%
2.3 Liquidity
BIOX has a Current Ratio of 1.02. This is a normal value and indicates that BIOX is financially healthy and should not expect problems in meeting its short term obligations.
BIOX's Current ratio of 1.02 is on the low side compared to the rest of the industry. BIOX is outperformed by 91.46% of its industry peers.
A Quick Ratio of 0.74 indicates that BIOX may have some problems paying its short term obligations.
BIOX has a Quick ratio of 0.74. This is amonst the worse of the industry: BIOX underperforms 85.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BIOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1457.63%.
BIOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.28%.
The Revenue has been growing by 14.09% on average over the past years. This is quite good.
EPS 1Y (TTM)-1457.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2233.33%
Revenue 1Y (TTM)-28.28%
Revenue growth 3Y0.49%
Revenue growth 5Y14.09%
Sales Q2Q%-39.76%
3.2 Future
The Earnings Per Share is expected to grow by 26.67% on average over the next years. This is a very strong growth
BIOX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y68.16%
EPS Next 2Y49.09%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-6.3%
Revenue Next 2Y6.65%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BIOX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIOX indicates a somewhat cheap valuation: BIOX is cheaper than 73.17% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BIOX is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.19 | ||
| EV/EBITDA | 7.84 |
4.3 Compensation for Growth
BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.09%
EPS Next 3Y39.47%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.92
-0.08 (-4%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners32.2%
Inst Owner Change-0.29%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap120.40M
Revenue(TTM)333.38M
Net Income(TTM)-9059700
Analysts80
Price Target5.48 (185.42%)
Short Float %1.73%
Short Ratio0.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.45%
Min EPS beat(2)-89.82%
Max EPS beat(2)86.93%
EPS beat(4)1
Avg EPS beat(4)-297.85%
Min EPS beat(4)-1076.47%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-217.21%
EPS beat(12)2
Avg EPS beat(12)-43.03%
EPS beat(16)3
Avg EPS beat(16)-46.14%
Revenue beat(2)0
Avg Revenue beat(2)-13.11%
Min Revenue beat(2)-19.15%
Max Revenue beat(2)-7.07%
Revenue beat(4)0
Avg Revenue beat(4)-13.33%
Min Revenue beat(4)-19.15%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-8.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.28%
Revenue beat(16)8
Avg Revenue beat(16)9.32%
PT rev (1m)0%
PT rev (3m)-27.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-221.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)-5.48%
Revenue NY rev (3m)-12.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.31 | ||
| P/FCF | 4.19 | ||
| P/OCF | 2.55 | ||
| P/B | 0.39 | ||
| P/tB | 8.32 | ||
| EV/EBITDA | 7.84 |
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)0.46
FCFY23.85%
OCF(TTM)0.75
OCFY39.15%
SpS6.11
BVpS4.92
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROCE | 4.68% | ||
| ROIC | 3.08% | ||
| ROICexc | 3.36% | ||
| ROICexgc | 10.83% | ||
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% | ||
| FCFM | 7.49% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 77.16% | ||
| Cap/Sales | 4.81% | ||
| Interest Coverage | 0.88 | ||
| Cash Conversion | 103.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-Score4
WACC8.9%
ROIC/WACC0.35
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1457.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2233.33%
EPS Next Y68.16%
EPS Next 2Y49.09%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-28.28%
Revenue growth 3Y0.49%
Revenue growth 5Y14.09%
Sales Q2Q%-39.76%
Revenue Next Year-6.3%
Revenue Next 2Y6.65%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-42.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y304.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y395.75%
OCF growth 3YN/A
OCF growth 5YN/A
BIOCERES CROP SOLUTIONS CORP / BIOX FAQ
Can you provide the ChartMill fundamental rating for BIOCERES CROP SOLUTIONS CORP?
ChartMill assigns a fundamental rating of 3 / 10 to BIOX.
What is the valuation status for BIOX stock?
ChartMill assigns a valuation rating of 3 / 10 to BIOCERES CROP SOLUTIONS CORP (BIOX). This can be considered as Overvalued.
Can you provide the profitability details for BIOCERES CROP SOLUTIONS CORP?
BIOCERES CROP SOLUTIONS CORP (BIOX) has a profitability rating of 2 / 10.
What is the expected EPS growth for BIOCERES CROP SOLUTIONS CORP (BIOX) stock?
The Earnings per Share (EPS) of BIOCERES CROP SOLUTIONS CORP (BIOX) is expected to grow by 68.16% in the next year.